Get full insights on how cell avidity can be applied to CAR-NK development
Learn from our Field Application Scientist how CAR-NK therapy emerges as a novel cell therapy for cancer, and how measuring cell avidity provides valuable information that enables researchers to select the best candidates most likely to succeed in vivo and in clinical trials.
Leading research teams reveal cell avidity of CAR-NK cells as the best and earliest predictive parameter for 𝙞𝙣 𝙫𝙞𝙫𝙤 tumor control
Tumors are often able to escape from immune surveillance using trogocytosis, a mechanism where innate cells accumulate inhibitory molecules torn from the tumor. Recent work using cell avidity measurements by the Gottschalk lab at St. Jude Children’s Research Hospital (published in Nature Biotechnology) and the Rezvani lab at MD Anderson Cancer Center (published in Nature Medicine) revealed new mechanisms to overcome trogocytosis-mediated escape and improve solid tumor clearance in vivo.
Dr. Chockley presented his work published in Nature Biotechnology “Synapse-tuned CARs enhance immune cell anti-tumor activity”.
"Most influential were the avidity measurements that directly interrogated the strength of the synapse."
- Cell avidity is used to identify CAR-NK cells with improved synapse strength and in vivo tumor clearance, leading to potential improvements in therapeutic efficacy.
- Enhanced avidity helps to overcome trogocytosis-mediated relapse and improves in vivo tumor clearance, thus prolonging the survival rate of CAR-NK cells by tuning synapse interactions.
- High-avidity CAR-NK cells display lower levels of trogocytosis than low-avidity cells.
Schematic figure of the z-Movi workflow depicting measurements of two different immune-cell populations with different avidities to the monolayer of target cells and the resulting avidity curves.
Why use the z-Movi?
Because it is the only tool that allows you to reliably select the best CAR-NK and other immune cell variants, saving you invaluable time and costs.